News

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed…

2 years ago

Surgery Partners, Inc. Announces Proposed Secondary Offering of Common Stock

BRENTWOOD, Tenn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (Nasdaq: SGRY) (“Surgery Partners” or the “Company”) today announced…

2 years ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology…

2 years ago

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts…

2 years ago

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the…

2 years ago

Malachite Innovations Changes its Name to Range Impact and Adopts New Ticker Symbol “RNGE”

CLEVELAND, OHIO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Malachite Innovations, Inc. announces that it has changed its name to Range…

2 years ago

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a…

2 years ago

Histogen Announces Second Adjournment of Special Meeting of Stockholders

Histogen Special Meeting QR Code Histogen Special Meeting QR Code Meeting Adjourned for a Final Time to January 4, 2024…

2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a…

2 years ago

Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 In Patients with Endometriosis

LUND, SE / ACCESSWIRE / December 15, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announces today that the…

2 years ago